Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

BMS CA209436: A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non-Hodgkins Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and n
Brief Description  
Primary: Evaluate the safey and tolerability of the combination of nivolumab and brentuximab in subjects with the diagnosis of relapsed, refractory DLBCL, PTCL, and CTCL. To assess the clinical benefit of nivolumab and brentuximab vedotin combination regimen in subjects with diagnosis of relapsed/ refractory DLBCL, relapsed/ refractory DLBCL, relapsed/ refractory PTCL, (excluding ALCL) and relapsed/ refractory CTCL, as measured by ORR, and portion of patients achieving PR or CR.
Who may be Eligible  
Please contact us for eligibility criteria.
Non-Hodgkin's Lymphoma
Start Date  
IRB Number  
Principal Investigator  
Ghosh, Nilanjan
Contact Name  
Sally P Ware

For More Information, Contact  Sally  P, Ware
Phone:  980-442-2030 Fax:    
Email:  Sally.Ware@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204